- 01GLP trial shows 12% maize silage yield increase.
- 02Estimated farmer ROI up to 20x with ~1100 AUD/ha revenue uplift.
- 03Commercialisation progress is supported by recent funding, but distribution deals are pending.
Terragen Holdings (ASX: TGH) announced positive independent trial results for its GLP biostimulant, showing a significant 12% increase in maize silage yield and an estimated ROI of up to 20x for farmers, underpinning its commercialisation strategy.
This translates to a substantial 8.81 t/ha uplift in productivity.
The product, applied at a rate of 4 L/ha, incurred a cost of approximately 55 AUD per hectare, while generating an estimated ~1100 AUD/ha in additional gross revenue for farmers.
The trial, conducted with 13 replicated data sets, showed GLP outperformed all other treatments, supporting its near-term commercialisation potential.
Solid ROI and Revenue Uplift
Using a silage price of 125 AUD per wet tonne, the increase in yield delivered a significant boost to gross revenue for farmers.
The economic benefits are clear.
The calculated return on investment (ROI) for farmers reached up to an impressive 20x.
This figure is based on the modest cost of GLP application against the substantial revenue gains.
In the trial, the maximum observed yield reached 90 t/ha, highlighting the product's effectiveness in optimising crop output.
Funding and Commercialisation
These positive results emerge as Terragen continues its commercialisation push.
The company completed a ~7.0 million equity raise in February 2026, specifically aimed at accelerating global commercialisation efforts.
Terragen has also been strategic in its development. Its half-year report noted a shift towards a more targeted, cash-conscious development and trials strategy to manage its growth efficiently.
While the trial results are compelling, Terragen is yet to announce any binding distribution agreements for GLP.
This remains a key area for execution in its commercialisation pathway.
Acknowledged Investor Risks
Investors should note that trial results can be environment-specific, which may limit their generalisability across different farming conditions.
Terragen faces execution risks in scaling manufacturing to meet demand and in securing crucial partnerships for distribution.
Market conditions, such as drought, have previously impacted the company's sales, particularly within the dairy sector.
Additionally, regulatory timelines for product approvals can introduce uncertainty and potential delays in market access.
Get the wire before the market opens.
The ASX small-cap stories that matter, filed before 9am AEST. Curated by the Small Caps desk.